BeyondSpring Inc (NASDAQ:BYSI) — Market Cap & Net Worth
Market Cap & Net Worth: BeyondSpring Inc (BYSI)
BeyondSpring Inc (NASDAQ:BYSI) has a market capitalization of $61.27 Million ($61.27 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21085 globally and #4515 in its home market, demonstrating a -10.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BeyondSpring Inc's stock price $1.49 by its total outstanding shares 41119820 (41.12 Million). Analyse BYSI cash generation efficiency to see how efficiently the company converts income to cash.
BeyondSpring Inc Market Cap History: 2017 to 2026
BeyondSpring Inc's market capitalization history from 2017 to 2026. Data shows change from $1.20 Billion to $61.27 Million (-23.26% CAGR).
Index Memberships
BeyondSpring Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #604 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2037 of 3165 |
Weight: BeyondSpring Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BeyondSpring Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BeyondSpring Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.14x
BeyondSpring Inc's market cap is 21.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $501.66 Million | $180.00K | -$60.97 Million | 2787.01x | N/A |
| 2021 | $186.27 Million | $1.35 Million | -$64.18 Million | 137.88x | N/A |
| 2022 | $77.31 Million | $1.35 Million | -$33.28 Million | 57.22x | N/A |
| 2023 | $37.01 Million | $1.75 Million | -$21.03 Million | 21.14x | N/A |
Competitor Companies of BYSI by Market Capitalization
Companies near BeyondSpring Inc in the global market cap rankings as of May 4, 2026.
Key companies related to BeyondSpring Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BeyondSpring Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, BeyondSpring Inc's market cap moved from $1.20 Billion to $ 61.27 Million, with a yearly change of -23.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $61.27 Million | -8.59% |
| 2025 | $67.03 Million | 0.00% |
| 2024 | $67.03 Million | +81.11% |
| 2023 | $37.01 Million | -52.13% |
| 2022 | $77.31 Million | -58.50% |
| 2021 | $186.27 Million | -62.87% |
| 2020 | $501.66 Million | -21.29% |
| 2019 | $637.36 Million | -17.33% |
| 2018 | $771.00 Million | -35.52% |
| 2017 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of BeyondSpring Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.27 Million USD |
| MoneyControl | $61.27 Million USD |
| MarketWatch | $61.27 Million USD |
| marketcap.company | $61.27 Million USD |
| Reuters | $61.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-canc… Read more